[Left ventricular systolic dysfunction in cardiomyopathies].
Of the three physiopathological types of cardiomyopathy, dilated, hypertrophic and restrictive, it is the first which characteristically shows major left ventricular systolic dysfunction. The left ventricular volumes are increased, the ventricle becomes spherical and global ejection fraction decreases with diffuse or segmental wall motion abnormalities. The left ventricular mass is increased in an excentrical fashion with wall thinning. Isovolumic contraction is slower, the ejection time is shorter and, above all, the indices of contractility such as maximal velocity of the contractile elements ... are very abnormal and do not improve after positive inotropic stimulation.
Bouhour
J B
JB
Clinique cardiologique et des maladies vasculaires, hôpital Guillaume et René-Laennec, Nantes.
Langlard
J M
JM
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D009202:Cardiomyopathies / Q000150:complications* / Q000235:genetics / Q000503:physiopathology; D002311:Cardiomyopathy, Dilated / Q000150:complications / Q000235:genetics / Q000503:physiopathology; D002316:Cardiotonic Agents / Q000627:therapeutic use; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D013318:Stroke Volume; D013599:Systole; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents; D010726:Phosphodiesterase Inhibitors